"He said the open nature of the project demystified science and revealed the number of roadblocks the students had faced in coming up with the final product, which involved three complicated chemical steps. “With science results you can be presented with a polished finished product that hides the false steps along the way,” he said. “The students’ real-time diary highlights their whole process, and is a very transparent way of doing things.”... He said unfortunately the students would not be able to sell their drug to the US market. While the drug can be bought in Australia for about A$13 for a packet of 50, there are a number of complicated legal roadblocks in the way of producing and selling it in the US. “Turing has the exclusive rights to sell it, even though the drug is no longer under patent,” Todd said. “The ridiculousness of this legal loophole means if we wanted to launch it as drug in the US we’d have to go through a whole new clinical trial because we would have to compare the Sydney Grammar stuff with the officially sanctioned stuff, and Turing would have to give us the drug to allow those comparisons to be made."
Issues and developments related to IP, AI, and OM, examined in the IP and tech ethics graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology", coming in Summer 2025, includes major chapters on IP, AI, OM, and other emerging technologies (IoT, drones, robots, autonomous vehicles, VR/AR). Kip Currier, PhD, JD
Showing posts with label exclusive rights to sell. Show all posts
Showing posts with label exclusive rights to sell. Show all posts
Thursday, December 1, 2016
Australian students recreate Martin Shkreli price-hike drug in school lab; Guardian, 11/30/16
Melissa Davey, Guardian; Australian students recreate Martin Shkreli price-hike drug in school lab:
Subscribe to:
Posts (Atom)